GLP-1 Constipation: The Step-by-Step Laxative Protocol That Actually Works

Constipation is the second-most-common GLP-1 side effect after nausea. In STEP-1 (Wilding 2021^[1]) it affected ~24% of semaglutide patients vs ~11% on placebo; in SURMOUNT-1 (Jastreboff 2022^[2]) it affected ~17% of tirzepatide 10 mg patients vs ~6% on placebo. The mechanism is published (Maselli 2021^[3]): slowed gastric emptying, reduced food and fluid intake during dose escalation, and a dehydrated colon. The good news is that the management algorithm is boring and well-evidenced — the AGA and ACG published a joint guideline in 2023 (Chang & Chey^[6]) spelling out the step-up ladder. This article walks through the four steps: lifestyle, OTC osmotic plus stimulant, prescription secretagogues, and specialist referral — with the published evidence behind each.

The honest summary

• Constipation hits 17–24% of GLP-1 patients. STEP-1 (Wilding 2021^[1]) reported 24.2% on semaglutide 2.4 mg vs 11.1% on placebo; SURMOUNT-1 (Jastreboff 2022^[2]) reported 16.8–11.7% across tirzepatide 5/10/15 mg vs 5.8% placebo. Most cases are mild-to-moderate and dose-escalation-related, not permanent.
• The mechanism is slowed gastric emptying plus dehydration. Maselli & Camilleri 2021^[3] reviewed the gastric physiology data: GLP-1 receptor activation slows antral motility, prolongs gastric retention, and indirectly reduces colonic water content when food and fluid intake drop during titration.
• The 4-step ladder is published. The AGA/ACG 2023 joint guideline (Chang & Chey^[6]) and the systematic review by Paré 2014^[8] both support: (1) lifestyle and fiber, (2) OTC PEG 3350 plus senna PRN, (3) prescription secretagogue (linaclotide, lubiprostone, plecanatide), (4) prucalopride or GI referral.
• Iron supplements compound the problem. Oral ferrous sulfate is a well-known constipating agent. If a patient also needs iron repletion, switching to bisglycinate or alternate-day dosing reduces the gastrointestinal burden.

How common is constipation on each GLP-1?

The randomized phase-3 obesity trials report constipation in a narrow band:

• Semaglutide 2.4 mg (STEP-1, Wilding 2021^[1]): 24.2% vs 11.1% placebo.
• Tirzepatide 5/10/15 mg (SURMOUNT-1, Jastreboff 2022^[2]): 11.7–17.1% vs 5.8% placebo.
• Liraglutide 3.0 mg: ~20% in SCALE Obesity & Prediabetes — in the same range.
• Oral semaglutide (Rybelsus): 5–9% in PIONEER trials — lower because the dose is lower and the pill matrix delivers a smaller systemic exposure than the 2.4 mg injection.

Real-world reporting in retrospective claims data and case series tracks higher than the trial numbers, partly because community patients titrate faster than the protocol mandates and partly because pre-existing functional constipation gets amplified rather than newly caused.

The mechanism in one paragraph

GLP-1 receptor agonists slow gastric emptying via central and peripheral vagal mechanisms (Maselli & Camilleri 2021^[3]). Antral motility is reduced; pyloric tone is increased. Food sits in the stomach longer, which is part of the therapeutic satiety effect — but the same physiology means that total daily food and fluid intake drops by a third or more during titration. Less fluid in equals less fluid in the colon. Less fiber in equals less stool bulk. The colonic transit time stretches, water reabsorption is more complete, and stool becomes drier and harder — Bristol Stool types 1–2 on the Lewis & Heaton scale^[5].

Defining constipation: Rome IV and the Bristol Stool Scale

The Rome IV criteria (Mearin 2016, Gastroenterology^[4]) define functional constipation as two or more of the following for at least three months, with symptom onset at least six months prior:

• Straining during more than 25% of defecations.
• Lumpy or hard stools (Bristol types 1–2^[5]) in more than 25% of defecations.
• Sensation of incomplete evacuation in more than 25%.
• Sensation of anorectal obstruction or blockage in more than 25%.
• Manual maneuvers to facilitate more than 25% of defecations.
• Fewer than three spontaneous bowel movements per week.

On a GLP-1, the dose-escalation phase produces an acute functional constipation that does not meet the full Rome IV three-month criterion, but the management algorithm is the same. The Bristol Stool Form Scale^[5] is the bedside tracking tool: types 3–4 are the target; types 1–2 indicate the protocol needs escalation.

Step 1: lifestyle (week 1–2 of titration)

The AGA/ACG 2023 guideline (Chang & Chey^[6]) opens with non-pharmacological measures because the evidence base for them is the largest. The three load-bearing levers for GLP-1 patients are:

• Hydration: 80–100 oz / 2.4–3.0 L per day. Coffee and tea count; alcohol does not. Patients on a GLP-1 reliably under-drink because thirst cues are blunted alongside hunger; setting a calendar-driven schedule (a glass with each medication, each meal, each transition) works better than relying on thirst.
• Fiber: 25–30 g per day, psyllium-based. Psyllium husk (Metamucil) 5–10 g per day is the best-evidenced soluble fiber for stool consistency. Inulin and other prebiotic fibers cause more gas and bloating, which a GLP-1 patient with already-delayed gastric emptying does not need.
• Daily walking: 30+ minutes. The colon-motility benefit of post-meal ambulation is modest but real; sedentary patients have measurably slower transit times.

Most patients who hit all three for two consecutive weeks will resolve mild dose-escalation constipation without further intervention. Patients who do not should advance to Step 2 rather than waiting longer.

Step 2: OTC osmotic plus stimulant (if Step 1 insufficient)

Polyethylene glycol 3350 (PEG 3350, marketed as MiraLAX) is the first-line OTC osmotic. Mínguez 2016^[7] reviewed PEG 3350 in functional constipation and fecal impaction and reported response rates of 50–70% at the standard 17 g per day dose. PEG works by retaining water in the colon — the exact mechanism a GLP-1 patient is short on — with minimal absorption, no electrolyte disturbance at standard dose, and no habituation.

Senna 8.6–17.2 mg at bedtime PRN is the stimulant complement. Paré 2014^[8] systematically reviewed stimulant and nonstimulant laxatives and concluded the PEG 3350 + senna stack outperforms either agent alone in chronic functional constipation. Magnesium oxide 500–1,000 mg daily and magnesium citrate are reasonable alternatives for patients who cannot tolerate PEG 3350; check renal function before chronic magnesium use.

Avoid long-term bisacodyl. Bisacodyl is appropriate for short-term rescue but chronic daily use can produce electrolyte abnormalities and is not recommended beyond 1–2 weeks of continuous use.

Step 3: prescription secretagogues (if Step 2 fails 4 weeks)

The AGA/ACG 2023 guideline^[6] gives a strong recommendation for prescription intestinal secretagogues as the next rung. These agents add water and chloride to the gut lumen rather than osmotically pulling it in.

• Linaclotide (Linzess) 145–290 mcg daily. The 26-week RCT by Chey 2012^[9] showed a statistically significant increase in complete spontaneous bowel movements vs placebo across both doses. Diarrhea is the dose-limiting side effect.
• Lubiprostone (Amitiza) 24 mcg twice daily. Chloride-channel activator; nausea is the main side effect and can compound the GLP-1 nausea, so it is usually not first-line in this population.
• Plecanatide (Trulance) 3 mg daily. Similar mechanism to linaclotide with a slightly different side-effect profile.
• Tenapanor (Ibsrela) 50 mg twice daily. NHE3 inhibitor approved for IBS-C; can be tried in patients with overlapping IBS-C and GLP-1 constipation.

Insurance coverage of these agents is patchy and prior authorization is the rule. Cash-pay prices land in the $400–500 per month range without manufacturer assistance programs.

Step 4: specialist (severe or refractory)

Patients who fail Step 3 after four to eight weeks of adequate dosing should be referred. The options at this rung include:

• Prucalopride (Motegrity) 2 mg daily. A highly selective 5-HT4 receptor agonist; Camilleri 2008 NEJM^[10] randomized 620 patients with severe chronic constipation and demonstrated a significant increase in spontaneous complete bowel movements vs placebo. Cardiac safety has been re-confirmed since earlier 5-HT4 agents were withdrawn.
• GI referral with anorectal manometry and balloon-expulsion testing to rule out dyssynergic defecation, which does not respond to laxatives and requires pelvic-floor physical therapy.
• Sitz marker (colonic transit) study to characterize slow-transit constipation vs normal-transit constipation; treatment differs.
• Colonoscopy if alarm features are present (see red flags below).

Magnitude: how each step changes spontaneous bowel movements per week

Iron supplements and other compounding drugs

Ferrous sulfate, the cheapest and most prescribed oral iron, constipates almost everyone. If a GLP-1 patient has concurrent iron deficiency (see our companion article on ferritin and hair loss), switching to ferrous bisglycinate or alternate-day dosing materially reduces the GI burden without sacrificing absorption efficiency. Other compounders worth screening for at the first visit:

• Anticholinergics: oxybutynin, diphenhydramine, tricyclic antidepressants.
• Opioids: any chronic opioid will cause opioid-induced constipation that overlays the GLP-1 effect. The PAMORAs — methylnaltrexone, naloxegol (Chey 2014 NEJM^[11]), naldemedine — target this specifically and do not cross the blood-brain barrier.
• Calcium-channel blockers: verapamil and diltiazem are particularly constipating.
• Calcium supplements: do not co-administer with oral iron (calcium impairs iron absorption); spacing them four hours apart is standard.

Red flags — when constipation needs urgent evaluation

• New-onset constipation after age 50 without an obvious trigger — warrants colonoscopy.
• Hematochezia or melena — visible or occult blood in stool.
• Weight loss disproportionate to the GLP-1 dose, especially with anorexia and night sweats.
• Family history of colorectal cancer or inflammatory bowel disease.
• Severe abdominal pain or distention, vomiting, or inability to pass flatus — rule out obstruction.
• Anemia, iron deficiency, or elevated inflammatory markers alongside new constipation.

Cost and insurance reality

OTC agents are universally accessible: MiraLAX retails around $15 per month; senna tablets around $5 per month; magnesium oxide pennies per dose. Prescription secretagogues are gated — linaclotide (Linzess) cash pay runs ~$400 per month, prucalopride (Motegrity) ~$500 per month, and most commercial plans require prior authorization documenting failed OTC and a trial of at least one secretagogue. Manufacturer copay cards drop commercial-insured patients to $0–30 per month at retail pharmacies; cash-pay patients can use GoodRx or pharmacy discount programs to land in the $200–300 range.

Related research and tools

• GLP-1 first 30 days survival guide — the lifestyle and hydration scaffolding that prevents Step-2 escalation
• GLP-1 side effect questions answered — nausea, fatigue, sulfur burps, and the other common dose-escalation issues
• GLP-1 and IBS — IBS-C overlap and the linaclotide / tenapanor calculus
• GLP-1 with Crohn's and ulcerative colitis — IBD management when GI motility is already dysregulated
• GLP-1 and GERD — PPI stacking — the upper-GI counterpart problem and its management
• GLP-1 and iron deficiency — oral iron compounds constipation; bisglycinate and alternate-day dosing reduce GI burden
• Wegovy constipation causes and relief — the semaglutide-specific drug page
• Mounjaro constipation causes and relief — the tirzepatide-specific drug page
• Ozempic constipation causes and relief — the type-2 diabetes semaglutide-specific page

Important disclaimer. This article is educational and does not constitute medical advice. Constipation that includes any of the red flags listed above should be evaluated by a clinician without delay. Laxative selection and escalation should be coordinated with the prescribing clinician, particularly for patients with renal impairment (magnesium caution), cardiovascular disease (5-HT4 historical concerns), inflammatory bowel disease, or pregnancy. PMIDs were verified live against the PubMed E-utilities API on 2026-05-29.

Last verified: 2026-05-29. Next review: every 12 months, or sooner if a new AGA/ACG or Rome consensus update is published.